Last update Oct. 17, 2024

Rosiglitazone

Likely Compatibility

Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.

Rosiglitazone is a thiazolidinedione used in conjunction with diet and exercise to normalise blood glucose levels in adults with type 2 diabetes mellitus. It is administered orally as one or two daily doses.

At the time of the last update, we found no published data on its excretion in breast milk.

Its pharmacokinetic data (very high percentage of plasma protein binding and large volume of distribution) make passage into breast milk in clinically significant quantities very unlikely.

Pending further published data on this drug in relation to lactation, safer known alternatives may be preferable, especially during the neonatal period and in case of prematurity.

There is inadequate evidence of the carcinogenic potential of rosiglitiazone. IARC 2016, p.373)

Thiazolidinediones increase insulin sensitivity. Oral antidiabetics are not helpful in type 1 diabetes. In type 2 diabetes, diet, exercise and breastfeeding will improve blood glucose levels.


See below the information of this related product:

  • Maternal Diabetes mellitus (Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.)

Alternatives

  • Acarbose (Safe product and/or breastfeeding is the best option.)
  • Glibenclamide (Safe product and/or breastfeeding is the best option.)
  • Glipizide (Safe product and/or breastfeeding is the best option.)
  • Hypocaloric Diet (Safe product and/or breastfeeding is the best option.)
  • Insulin (Safe product and/or breastfeeding is the best option.)
  • Metformin Hydrochloride (Safe product and/or breastfeeding is the best option.)
  • Miglitol (Safe product and/or breastfeeding is the best option.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

Rosiglitazone is also known as


Rosiglitazone in other languages or writings:

Groups

Rosiglitazone belongs to these groups or families:

Tradenames

Main tradenames from several countries containing Rosiglitazone in its composition:

  • Avandamet™. Contains other elements than Rosiglitazone in its composition
  • Avandaryl™. Contains other elements than Rosiglitazone in its composition
  • Avandia™
  • Glimide™

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 99 %
Molecular weight 357 daltons
Protein Binding 99.8 %
VD 0.25 l/Kg
pKa 6.84 -
Tmax 1 hours
T½ 3 - 4 hours

References

  1. IARC - WHO. International Agency for research on Cancer. Some Drugs and Herbal Products. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans Volume 108. 2016 Full text (link to original source)
  2. Serrano Aguayo P, García de Quirós Muñoz JM, Bretón Lesmes I, Cózar León MV. Tratamiento de enfermedades endocrinológicas durante la lactancia. [Endocrinologic diseases management during breastfeeding.] Med Clin (Barc). 2015 Jan 20;144(2):73-9. Abstract

Total visits

5,093

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Instituto de Salud Infantil, Grecia-Institute of Child´s Health in Greece

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM